



INNOVATIONS IN COVID-19

Bridging opportunities
at Oswaldo Cruz Institute

NAPHTHOQUINONE DERIVATIVES ACTING ON SARS-COV-2 PROTEASES (COD. 2020.002)

COORDINATOR

Carlos Roberto Alves

RESEARCH AREA

New Drugs

DEVELOPMENT STAGE

Level 1 - TRL - Basic principles observed and reported. MRL - Basic principles observed and reported.

PROPOSITION / APPLICATION

The absence of COVID-19 chemotherapy drugs is one of the impediments in combating the pandemic. Thus, there is an urgent need to optimize new protease inhibitors.

INNOVATION

To effectively achieve protease inhibition to block SARS-CoV-2 replication. The compounds tested in this strategy can be easily synthesized in national laboratories.

OPPORTUNITY

This research proposes new anti-SARS-CoV-2 compounds that reduce the signs and symptoms of covid-19, thus favouring the recuperation of ill patients.

CONTACT

nit@ioc.fiocruz.br